When my one-month-old daughter was diagnosed with biliary atresia — a rare disease that for most of human history was 100% fatal — I entered a world where hope and terror coexist.
Thanks to pioneers who pushed the envelope when everyone else had given up, at thirteen months old she underwent a liver transplant in Pittsburgh, and today she is alive and thriving in college.(RELATED: You May Have Missed This, But A Notorious American Lobby Lost Big In Court)
So I understand intimately why families facing devastating illnesses want access to innovative therapies. But innovation only works if the science ecosystem can differentiate true innovation from failure.
A recent Wall Street Journal column argues that the U.S. Food and Drug Administration (FDA) is standing in the way of hope for rare disease patients. It frames the debate as a simple moral choice: let patients try promising…




